Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

) in late April, InterMune, Roche and Pharmasset, Inc. reported top-line results from the novel Phase 1 INFORM-1 clinical trial evaluating ITMN-191 in combination with nucleoside polymerase inhibitor R7128 but no interferon or ribavirin in patients with HCV infection. Data from the first four dosage cohorts of the study were as follows:
  • The combination resulted in sustained viral load reductions over the dosing period in all cohorts. Seventy percent (70%) of patients in the last two dosage cohorts had levels of virus in their blood below the limit of quantification by the diagnostic assay at day 14, and 33% of these patients had no detectable virus in their blood at day 14.
  • Patients receiving the combination of ITMN-191 and R7128 for 14 days experienced a median reduction in viral levels of -4.8 to -5.2 Log10 IU/mL in the last two cohorts tested.
  • In the early low-dose groups, after only three days of dosing, the mean reduction in viral load levels was 0.6 log10 greater with combination treatment (-2.9) compared to the performance of the individual compounds when given as monotherapy (-0.46 and -1.84 for R7128 and R7227, respectively).
  • The combination was well tolerated over 14 days, with no treatment-related serious adverse events (SAEs), dose reductions or discontinuations. Pharmacokinetic analysis confirmed that there were no drug-drug interactions between the compounds.

  • On April 21, InterMune reported that based on these promising early results, the INFORM-1 study had been expanded to explore the interferon-free regimen in treatment-experienced patients; both treatment failures and null-responder HCV patients and would include twice-daily dosing of ITMN-191 and significantly higher total daily doses (600mg and 900mg twice daily) than those explored in the first four patient cohorts of
    '/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 30
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. InterMune to Present at Canaccord Adams Hepatitis C Conference
4. InterMune to Present at Citis 4th Annual Biotech Day
5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
8. InterMune Announces Issuance of U.S. Patent for ITMN-191
9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
11. InterMune to Present at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... (PRWEB) July 10, 2014 Women ... have access to an additional family planning option. ... to contraception at all levels of the health ... formulation of a widely used contraceptive—Pfizer’s Depo-Provera® (depot ... Burkina Faso is the first of four African ...
(Date:7/10/2014)... Francisco, CA (PRWEB) July 10, 2014 ... family closer together. The Archer Family purchased a ... contained within DNA, but ended up with a lifetime ... discoveries contained within the family members’ DNA genuinely brought ... had decided to search deeper into genetic history and ...
(Date:7/10/2014)... , July 10, 2014  Franciscan St. ... of capnography for respiratory monitoring outside the ... healthcare leaders in embracing state-of-the-art patient safety ... patients are breathing and can alert medical ... measuring the amount of carbon dioxide the ...
(Date:7/10/2014)... July 10, 2014   Ceres, Inc . (Nasdaq: ... company, announced today financial results for the three months ... its business. Ceres reported that the company ... performance this growing season in Brazil, which concluded in ... company,s sorghum evaluation areas for part of the growing ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... the Harvard Business Review (HBR), containing an ... , questioned the impact of IT investments. This has ... One of the dissenters of Carrs article is PRISM ... specializes in Outsourced Marketing Services and uses technology to ...
... eFilm to offer an integrated PAC (picture achieving and ... target market of hospitals and imaging centers. , ... milestone in our evolution as a healthcare software and ... our target market," said Rich Linden, Merge eFilm president ...
... Ill. Though electricity and telephones dont even exist at ... the next highly underserved segment to be wired by ... Monday. Motorola says Indian reservations could be the most ... ,When identifying the need for high-speed Internet access for ...
Cached Biology Technology:IT Does Matter! 2IT Does Matter! 3Merge eFilm to buy Ohio firm in $14M Deal 2Merge eFilm to buy Ohio firm in $14M Deal 3Motorola Canopy Wires Indian Reservations 2
(Date:7/11/2014)... Researchers have pioneered a revolutionary new way to ... Virtual Finger, allows scientists to move through digital ... using the flat surface of their computer screens. ... orders of magnitude more efficient, saving time, money ... areas of experimental biology. The software and its ...
(Date:7/11/2014)... to the hippocampus, the marginal division of the ... What is the impact degree of substance P ... memory function? Yan Yu and his team, College ... using immunofluorescence staining, that substance P receptor, neurokinin ... striatal marginal division of normal rats. Unilateral or ...
(Date:7/11/2014)... 11, 2014 Research and Markets ... Technology Market - Industry Analysis Size Share Growth Trends ... http://photos.prnewswire.com/prnh/20130307/600769 ... created a need for high level security in both ... authentication such as username and passwords, tokens etc. are ...
Breaking Biology News(10 mins):Virtual finger enables scientists to navigate and analyze complex 3D images 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2
... 8, 2011 When expressed (turned on), the ... the enzyme telomerase. Human cells can keep living ... i.e. the cells become immortal . Telomerase ... extend human cell life indefinitely. TA-65®  is a ...
... , NARRAGANSETT, RI -- June 7, 2011 -- Sunshine Menezes, ... Reporting, and 2010 Grantham Prize winner Alanna Mitchell announced the ... on the Environment. James Astill of The Economist will receive ... Them," a commanding 8-part special report on the state of ...
... only organisms that turn to caffeine for a pick-me-up. University ... can live on caffeine. One of them, known as ... outside a UI research laboratory. The research team says the ... works -- could in the future allow scientists to convert ...
Cached Biology News:A Molecule That Turns on the Immortality Gene! 2A Molecule That Turns on the Immortality Gene! 3$75,000 Grantham Prize winner announced 2$75,000 Grantham Prize winner announced 3University of Iowa researchers identify caffeine-consuming bacterium 2
Monoclonal Mouse Anti-Human Cytokeratin 16 (48 kD)...
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
Rabbit polyclonal to NCoR2, prediluted ( Abpromise for all tested applications). entrezGeneID: 9612 SwissProtID: Q9Y618...
Rabbit polyclonal to TRPM8 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 79054 SwissProtID: Q3YFM7...
Biology Products: